Lung. 2026 Nov 20;204(1):100. doi: 10.1007/s00408-026-00965-0.
ABSTRACT
PURPOSE: In the placebo-controlled FIBRONEER-IPF trial in patients with IPF, nerandomilast reduced decline in forced vital capacity (FVC), with benefits on clinical outcomes and favorable safety and tolerability. We evaluated the effects of nerandomilast in the US patients.
METHODS: Patients were randomized to receive nerandomilast 9 mg bid, nerandomilast 18 mg bid, or placebo, stratified by antifibrotic therapy (nintedanib/pirfenidone versus neither). In the US subgroup, we assessed change in FVC at week 52; time-to-event endpoints over the whole trial; adverse events over the whole trial.
RESULTS: Of 1177 patients, 196 (16.7%) were from the US. In US patients, adjusted mean (SE) changes in FVC (mL) were — 257.9 (33.6) with placebo, — 152.7 (32.9) with nerandomilast 9 mg bid (difference vs. placebo 105.2 [95% CI 13.0, 197.4]), and — 126.2 (36.9) with nerandomilast 18 mg bid (difference vs. placebo 131.7 [95% CI 33.8, 229.6]. Compared with placebo, the hazard ratios for time to first acute exacerbation of IPF, hospitalization for respiratory cause, or death were 0.91 (95% CI 0.49, 1.67) for nerandomilast 9 mg bid and 0.60 (95% CI 0.30, 1.22) for nerandomilast 18 mg bid. Adverse events led to treatment discontinuation in 17.1%, 12.9% and 10.7% of the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively.
CONCLUSION: The effects of nerandomilast 18 mg bid in US patients in the FIBRONEER-IPF trial were consistent with the overall population. Nerandomilast 18 mg bid slowed FVC decline, with numerical reductions in the risk of clinical outcomes, and favorable safety and tolerability.
PMID:43062734 | DOI:10.1007/s00408-026-00965-0
